Four states advanced psychedelic research legislation in five days — and not one pharmaceutical company was involved in any of them. Texas announced on March 31 that its $50M IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) initiative would proceed entirely state-led after no pharmaceutical company submitted a qualifying proposal. UTHealth Houston and UTMB anchor a 10-institution consortium making this the largest state-funded psychedelic clinical trial effort ever mounted — the state absorbing the compound-level clinical risk that pharmaceutical sponsors would normally carry. Mississippi had already signed HB314 on March 26 (SIG0100). Kentucky's General Assembly passed SB77 on April 1. Missouri's House passed HB1717 by 137-11 on April 2 — the first time this legislation advanced in four years of attempts. Within a single five-day window, four states either signed, passed, or advanced standalone psychedelic research funding bills.

The Weizmann Institute published a biosynthesis result in Science Advances: a single tobacco plant engineered with nine genes simultaneously producing five psychedelic compounds — psilocybin, psilocin, DMT, bufotenin, and 5-MeO-DMT — using AlphaFold3-optimized enzyme design to achieve a 40-fold yield improvement over prior plant biosynthesis approaches. Oxa Life's breathwork biofeedback wearable was acquired by Myant with consumer operations ending; Myant is pursuing clinical and medical certification for the underlying technology. West Virginia SB906, which would have created the first statutory psilocybin prescription pathway in the U.S., died in House committee when the legislative session ended March 14 and never reached the governor's desk. Frontiers in Medicine published a 16-article research collection on digital mindfulness interventions.